Subscribe
pills-istock-525984851-1
sprng23 / iStockphoto.com
5 March 2019Big Pharma

CJEU opinion on SPC referral is ‘overdue’, say lawyers

An opinion on whether a supplementary protection certificate can be granted to an owner of a drug patent when the marketing authorisation is held by a third party is overdue, lawyers told LSIPR.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
UK court overturns Genentech patent, cites Brexit in CJEU referral
1 March 2019   The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Big Pharma
UK court overturns Genentech patent, cites Brexit in CJEU referral
1 March 2019   The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More on this story

Big Pharma
UK court overturns Genentech patent, cites Brexit in CJEU referral
1 March 2019   The patents division of the English High Court has found that a patent owned by Genentech is invalid and denied the biotechnology company’s application for a supplementary protection certificate.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Attorney v examiner: Navigating patenting's AI tools ‘arms race’
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool